Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QYHJ Granules vs Xeloda in Metastatic Pancreatic Cancer
NCT01796782Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of Qingyi Huaji in pancreatic cancer (PC) (2 arms), sponsored by Fudan University. Primary endpoint: Overall Survival at 3 years. Status: unknown.
02
Drugs
Qingyi Huaji
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01796782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796782.